Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer – The Herald | HeraldOnline.com

by lowes1 on September 26, 2013

Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer
The Herald | HeraldOnline.com
CAMBRIDGE, Mass. — Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 2 trial of defactinib (VS-6063), a potent inhibitor
Verastem starts phase I trial of defactinib in Japanpharmabiz.com

all 2 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: